ELITE PHARMACEUTICALS INC /NV/ 8-K

What Happened
Elite Pharmaceuticals, Inc. (ELTP) filed an 8-K on February 11, 2026 announcing results of operations and financial condition for the third quarter of fiscal year 2026 (quarter ended December 31, 2025). The company issued a press release (Exhibit 99.1) and scheduled a conference call for Wednesday, February 18, 2026 at 11:30 AM EST to discuss the quarterly results.

Key Details

• The filing covers Q3 FY2026 results for the quarter ended December 31, 2025; the press release is attached as Exhibit 99.1.
• Conference call: Feb 18, 2026 at 11:30 AM EST; domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840.
• Questions: email dianne@elitepharma.com; general questions due by 5:00 PM EST on Feb 16, 2026; financial questions due by 7:00 PM EST on Feb 17, 2026.
• The disclosure was furnished under Regulation FD and the exhibit is furnished (not “filed”) under Item 9.01, so it is not subject to Section 18 liability or automatic incorporation by reference.

Why It Matters
This 8-K signals that Elite will publicly present its quarterly earnings and related financial details on Feb 18 — an event investors can use to assess recent revenue, profitability and operational trends. The conference call and accompanying press release are the primary sources for the company’s Q3 financial metrics; investors should review those materials and listen to the call for concrete figures and management commentary before making decisions.